Viatris Swats Away Concerns Over Divestment Valuations
As US-Based Firm Updates On Glatiramer And Botox Biosimilar
Executive Summary
Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.